Welcome to our dedicated page for BLU news (Ticker: BLU), a resource for investors and traders seeking the latest updates and insights on BLU stock.
BELLUS Health Inc. (BLU) is an innovative biopharmaceutical development company dedicated to creating novel therapeutics for conditions with high unmet medical needs. Based in Canada, the company’s flagship project is BLU-5937, a groundbreaking drug candidate designed to treat chronic cough. Chronic cough, persisting for over eight weeks, significantly impacts the quality of life of more than 2.7 million patients in the United States alone. By targeting the P2X3 receptor, BLU-5937 offers a promising solution for patients who do not respond to existing treatments.
The drug candidate is a potent, highly selective, orally bioavailable small molecule antagonist of the P2X3 receptor, making it a potential best-in-class treatment option. The rights to BLU-5937 were acquired through a license agreement with the Neomed Institute in February 2017.
Beyond its lead project, BELLUS Health has vested interests in various partnered drug development initiatives, showcasing its broad commitment to addressing diverse medical challenges. The company's strategic partnerships and cutting-edge research underscore its pivotal role in the biopharmaceutical industry.
With continuous advancements and strong economic interests in multiple projects, BELLUS Health is positioned as a key player in developing revolutionary therapies that could significantly improve patients' lives. Investors and stakeholders remain keenly interested in the company's progress and future potential.
BELLUS Health reported its Q1 2021 financial results, highlighting ongoing clinical trials for BLU-5937 targeting refractory chronic cough and chronic pruritus. The company had cash reserves of US$81.9 million, down from US$98.3 million at year-end 2020, and continues to project sufficient funds to support operations through 2022. The net loss for the quarter was US$15.8 million, resulting in a loss per share of US$0.20. The increase in R&D expenses to US$12.4 million reflects heightened investment in clinical trials, up 91% year-over-year. Topline results from both trials are anticipated in Q4 2021.
BELLUS Health Inc. (Nasdaq:BLU) announced the acceptance of three abstracts on its product candidate, BLU-5937, for presentation at the American Thoracic Society 2021 International Conference scheduled from May 14-19, 2021. Highlights include a mini symposium titled Improvements in Cough Frequency and two poster presentations focusing on the design of the SOOTHE Phase 2b study and the burden of disease in patients with refractory chronic cough (RCC). Currently, RCC affects approximately 9 million patients in the U.S., with no specific approved therapies.
BELLUS Health (Nasdaq:BLU) announces that President and CEO Roberto Bellini will present a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on April 20, 2021, at 2:00 p.m. ET. BELLUS Health focuses on developing novel therapeutics for refractory chronic cough and hypersensitization-related disorders. Their lead candidate, BLU-5937, addresses refractory chronic cough, affecting around 9 million patients in the U.S., and chronic pruritus associated with atopic dermatitis. Currently, no specific therapy exists for these conditions, highlighting the need for innovative treatments.
BELLUS Health announced the appointment of Dr. William Mezzanotte to its Board of Directors. With over three decades in biopharmaceutical development, Dr. Mezzanotte has a proven track record, including the approval of 30 products. He aims to leverage his expertise to advance BLU-5937, a promising candidate for treating refractory chronic cough, which currently lacks FDA-approved therapies. The company estimates around 9 million patients in the U.S. suffer from this condition, highlighting the potential market impact of BLU-5937.
BELLUS Health reported its financial and operating results for the year ending December 31, 2020. The company is focused on developing BLU-5937, a treatment for chronic cough and related disorders. Highlights include the initiation of the Phase 2b SOOTHE trial for refractory chronic cough and the BLUEPRINT trial for chronic pruritus, both expecting topline results in Q4 2021. Financially, BELLUS had $98.3 million in cash as of year-end 2020, projecting sufficient funds until late 2022. However, they reported a net loss of $31.8 million for the year.
BELLUS Health, a clinical-stage biopharmaceutical company (Nasdaq: BLU; TSX: BLU), announced participation in two virtual healthcare investor conferences. The first, the Cowen 41st Annual Health Care Conference, will feature a panel discussion on respiratory/infections on March 1, 2021, at 10:20 a.m. EST. The second event, the H.C. Wainwright Global Life Sciences Conference, offers a prerecording starting March 9, 2021, at 7:00 a.m. EST. BELLUS Health develops therapeutics for chronic cough and chronic pruritus, addressing significant health issues affecting millions.
BELLUS Health (Nasdaq:BLU; TSX:BLU) is a clinical-stage biopharmaceutical firm focusing on treatments for refractory chronic cough and related disorders. On January 21-22, 2021, Dr. Catherine Bonuccelli and Dr. Denis Garceau will present significant data on BLU-5937 at the Eleventh International Virtual Cough Symposium. Key presentations include findings from the Phase 2a RELIEF trial and preclinical data on BLU-5937 as a P2X3 receptor antagonist for chronic pruritus in atopic dermatitis. Details will be accessible on their website post-conference.
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) has entered a Sales Agreement with Jefferies LLC, allowing the potential sale of common shares worth up to US$50 million through at-the-market distributions. Sales will occur exclusively in the U.S., with no sales in Canada. The company has filed a prospectus supplement and base shelf prospectus under SEC's registration statement effective December 23, 2020. BELLUS Health is focused on developing therapeutics for chronic cough and similar disorders, particularly its product candidate, BLU-5937.
BELLUS Health announced the dosing of the first patient in the Phase 2 BLUEPRINT trial for BLU-5937, aimed at treating chronic pruritus associated with atopic dermatitis. This trial is pivotal for assessing BLU-5937’s effectiveness as a P2X3 antagonist. It will involve approximately 128 adults and utilize a randomized, double-blind, placebo-controlled design. The primary endpoint is the change in the Worst Itch-Numeric Rating Scale after four weeks. The topline results are expected in Q4 2021, marking a significant development in addressing chronic itch, which affects many patients' quality of life.
BELLUS Health (Nasdaq:BLU) announced the dosing of the first patient in the Phase 2b SOOTHE trial for BLU-5937, targeting refractory chronic cough. This double-blind trial will evaluate three doses of BLU-5937 in 300 participants, aiming to establish its efficacy in reducing cough frequency. Interim results are expected mid-2021, with topline results anticipated in Q4 2021. The company believes BLU-5937 has potential not only for chronic cough but also for chronic pruritus and other hypersensitization-related disorders, addressing a significant unmet need.
FAQ
What is the market cap of BLU (BLU)?
What is BELLUS Health Inc.?
What is BLU-5937?
How does BLU-5937 work?
What is chronic cough?
When did BELLUS Health acquire the rights to BLU-5937?
Who are the potential beneficiaries of BLU-5937?
What other projects is BELLUS Health involved in?
Where is BELLUS Health headquartered?
Why is BLU-5937 considered a potential best-in-class drug?
How does BELLUS Health contribute to the biopharmaceutical industry?
